Cefditoren
From Wikipedia, the free encyclopedia
|
Cefditoren
|
|
| Systematic (IUPAC) name | |
| (2,2-dimethylpropanoyloxymethyl (6R,7R)-7-([(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino)-3 -[(Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C25H28N6O7S3 |
| Mol. mass | 620.721 g.mol-1 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Cefditoren is a third-generation cephalosporin antibiotic for oral use. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Contents |
[edit] Clinical use
[edit] Indications
Cefditoren is used to treat uncomplicated skin and skin structure infections. community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis (ABECB), pharyngitis, tonsillitis, and
[edit] Formulations
Cefditoren is available as 200 mg tablets.
trade name: Spectracef, Ceftorin
[edit] See also
[edit] External links
|
||||||||||||||||||||

